Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XBD173 in Pulmonary Artery Hypertension
NCT06035861Not yet recruiting
- Sponsor
- Imperial College London
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of emapunil in pulmonary arterial hypertension (PAH), sponsored by Imperial College London. Primary endpoints: Percentage change in plasma sVCAM1, e-selectin, GDF-15 and NT-proBNP at 6 weeks and Percentage change in total pulmonary resistance at 6 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
emapunil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06035861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035861.